The table wouldn't move no matter how hard he shoved.

Word always gets out no matter how careful you are.

无论你多么小心，总会有消息走漏。

Parallel lines will never meet no matter how far extended

无论延伸多长，平行线永不相交。

We have always been an independent people, no matter how they rewrite history

不管他们如何篡改历史，我们一直都是一个独立的民族。

No matter how often they were urged, they could not bring themselves to join in

就算别人说破了嘴皮，他们就是不加入。

Efficacy of postoperative concurrent radiotherapy and chemotherapy with Xeloda for stage ⅱ/ ⅲ rectal cancer

Ⅱ、Ⅲ期直肠癌根治术后放疗同步希罗达化疗的疗效

Objective: The effect of Xeloda combined with traditional Chinese Medicine Shen Ling Bai Zhu Decoction on the prognosis and Quality Of Life of elderly advanced colorectal carcinoma.

目的：观察希罗达（Xeloda）加中药参苓白术汤对晚期结直肠癌预后及生活质量的影响。

Objective To observe therapeutic effect and toxicity of the combination of xeloda with weekly dose of oxaliplatin in treatment of patients with advanced enteron tumor.

目的观察希罗达联合周剂量艾恒治疗晚期消化道肿瘤的疗效和毒副反应。

Capecitabine ( trade name" Xeloda") was first listed in Switzerland in August 1998.

卡培他滨于1998年8月在瑞士首次上市，商品名为Xeloda。

Xeloda combined with oxaliplatin in the treatment of advanced colorectal cancer

希罗达联合奥沙利铂治疗晚期结直肠癌的临床观察

Xeloda is a highly effective oral chemotherapy drug that can be used alone, or in combination with other drugs, for the treatment of colorectal ( including colon), stomach and breast cancer.

希罗达不管是单药还是联合其他药物在治疗结直肠癌（包括结肠癌）、胃癌、乳腺癌方面是非常高效的口服化疗药物。

Fifty-Two Patients with Metastatic Cervical Carcinoma Treated with Paclitaxel Plus Xeloda

卡培他滨联合紫杉醇治疗晚期转移性宫颈癌的临床研究

Objective To evaluate the response rate and adverse reaction of metastatic and recurrent breast cancer patients treated with xeloda.

目的观察希罗达治疗转移性或复发性乳腺癌的疗效及不良反应。

Methods: Xeloda 2 500 mg/ m 2/ day in dividing two dose per oral continued for two weeks, then stopped for one to two weeks.

方法：希罗达2500mg/m2·d-1，分2次口服，连续口服2周，停药1～2周；

It was began the registration of clinical trials in Beijing, Shanghai, Guangzhou and other places of the five national anticancer drug ′ s clinical trial research centers in November 1999. Then it was listed in China as the trade name "Xeloda".

于1999年11月开始由北京、上海、广州等地的5个国家抗肿瘤药物临床试验研究中心进行注册临床试验，并以商品名希罗达在中国上市。

The Clinical Observation of Xeloda Combined with Taxotere in the Treatment of Advanced Gastric Cancer

希罗达联合泰素帝治疗晚期胃癌的疗效观察

Clinical Observation to Postoperative Recurrence of Rectal Cancer Treated with Three Dimensional-conformal Radiotherapy Combined with Xeloda

三维适形放疗同步希罗达化疗治疗直肠癌术后复发的临床观察

Progress of Study on Prevention and Treatment of Xeloda Induced Hand-foot Syndrome by Measures of Chinese and Western Medicine

希罗达等致手足综合征中、西医防治措施研究进展

Conclusion Xeloda is suitable for the chemotherapy of malignant solid tumor of digestive tract.

结论希罗达可能适宜用于消化道恶性实体肿瘤化疗。

In the xeloda group, diarrhea in 28%, stomatitis in 16. 6% and hand-foot syndrome in 38. 9%.

希罗达组副反应主要为腹泻（28%）、手足综合征（38.9%）和口炎（16.6%）。

AIM: To investigate the effect of capecitabine ( xeloda) by preoperation administration on the microvessel density ( MVD) and expression of thymidine phosphorylase/ platelet-derived endothelial cell growth factor ( TP/ PD-ECGF) in patients with colorectal cancer.

目的：探讨术前希罗达化疗对结直肠癌胸苷磷酸化酶/血小板衍化内皮细胞生长因子（TP/PD-ECGF）表达、肿瘤组织微血管密度（MVD）的影响。